Nasopharyngeal Carcinoma FAQ
Nasopharyngeal Carcinoma FAQ
The questions international patients ask most: what drives cost, how long treatment and the stay in China take, which records to send before travelling, how insurance works, and what the side effects of radiotherapy involve.
What actually drives the cost
Three variables decide the figure. Whether chemotherapy is added to radiotherapy, which is stage-dependent rather than optional — concurrent cisplatin and an induction regimen each add a separate cost. How the radiotherapy is planned and delivered — intensity-modulated radiotherapy is the standard, and the planning and daily image guidance are part of the cost rather than extras. And how many cycles of induction chemotherapy are needed, which is usually two to three.
Comprehensive nasopharyngeal carcinoma treatment in China typically costs 30–50% of the equivalent treatment in Europe or the US, and the gap is widest in drug therapy. What we do not do is quote a number before there is a plan. The written assessment states what the treatment is expected to involve — radiotherapy alone, chemoradiotherapy, or induction followed by chemoradiotherapy — and cost follows from that rather than preceding it. Sending your records costs nothing and is the only way to get a figure that means something.
How long treatment takes, and how long to stay
Nasopharyngeal carcinoma is unusual among cancers in that the treatment is delivered over weeks as an outpatient, so the length of stay is set by the treatment rather than by an operation.
- Radiotherapy alone — six to seven weeks of daily treatment, Monday to Friday. Plan on staying for the whole course plus a few days for the planning scans and mask-fitting beforehand.
- Concurrent chemoradiotherapy — the same six to seven weeks, with cisplatin given every three weeks or weekly during it.
- Induction chemotherapy first — add roughly six to nine weeks before the radiotherapy starts, which makes the total stay three to four months.
- Assessment and planning only — endoscopy, biopsy, MRI, dental and audiology assessment can usually be completed in one to two weeks.
The practical consequence is that accommodation matters as much as the hospital. Because the treatment is outpatient and the side effects accumulate, patients are usually better off in stable accommodation near the hospital for the whole course than travelling back and forth. Visa and accommodation logistics are handled by the international patient team, and the plan is written before travel so the dates are chosen around the treatment rather than the other way round.
Chemotherapy, and continuing anything at home
What travels home after treatment is much less than in most cancers, because the treatment itself is not transferable. Radiotherapy cannot be continued elsewhere once a course is under way — the plan is drawn and delivered here — so the realistic question is not whether to finish the drug treatment at home but what surveillance is needed once it is over.
Two things do travel. The first is a surveillance plan: plasma EBV DNA measurement at stated intervals, MRI at stated intervals, and clinical examination of the nasopharynx. Because EBV DNA often rises before a scan changes, the blood test is the primary early-warning tool, and the plan needs to state where it will be measured and how a rising result will be acted on. The second is supportive medication — saliva substitutes, fluoride products for dental protection, and treatment for hypothyroidism if the thyroid was inside the radiation field. All are widely available, and all are specified in writing.
What to send before you travel
Send these before booking anything, because for this disease most of the planning can be done from them:
- The nasopharyngoscopy report and the biopsy pathology report, with the WHO type and the EBV status if it was reported
- MRI images of the nasopharynx, skull base and neck — the images, not only the radiologist's summary; the radiotherapy plan is drawn on them
- Plasma EBV DNA result, if measured
- PET-CT images if distant staging has been done
- Recent blood results, kidney function in particular if chemotherapy is planned
- Audiometry, and a dental assessment — both are baseline requirements before radiotherapy
Records in English are easiest, but the team works with translated documents — translation is part of the service. The most common delay is not the language but the imaging: an MRI report describing skull-base involvement without the images cannot be turned into a radiotherapy plan, and the images are what the radiation oncologist needs.
Insurance and payment
The network works with 70+ international insurers on direct billing, which means the bill is settled between the hospital and the insurer and you are not out of pocket for covered items. Before treatment, the team verifies your policy and confirms in writing what is covered and what is not — including whether radiotherapy, chemotherapy and a PD-1 inhibitor (if it were needed later) fall under the policy, and whether pre-authorisation is required.
Two features of this disease make pre-authorisation worth doing carefully. The first is that radiotherapy is charged for a course delivered over weeks rather than as a single event, and insurers vary in how they authorise that. The second is that the plan sometimes changes during treatment — concurrent chemotherapy added on the basis of how the tumour is responding, for instance — and it is better to know in advance how the insurer handles that than to discover it afterwards. If you are paying directly, the cost estimate is provided against the written plan and updated if the plan changes.
Follow-up after you go home
Follow-up in nasopharyngeal carcinoma has a specific shape, and it is built around two things: detecting recurrence, and managing the late effects of radiation.
Recurrence surveillance is led by plasma EBV DNA, measured at defined intervals, together with MRI of the nasopharynx and skull base and clinical examination with endoscopy. The blood test comes first in importance because a rising level often precedes any change on imaging. Where a recurrence is found in the neck it is often operable; where it is at the primary site, the options are endoscopic surgery or re-irradiation, and the earlier it is found the more of those options remain. Late effects are followed up separately and just as deliberately: dry mouth and its consequences for teeth, trismus, hearing, thyroid function if the gland was in the field, and — rarely but seriously — changes in the temporal lobes. These are written into the schedule with named tests and stated intervals, so your own doctor can execute the plan without guessing.
What the treatment feels like, and what helps
The side effects of radiotherapy to the nasopharynx are cumulative. Nothing much happens in the first week or two, then they build through the middle of the course and continue for a few weeks after it ends before settling.
- Sore mouth and throat, and difficulty eating — the main reason for weight loss during treatment, and the reason dietary support and, where needed, a feeding tube are planned for in advance rather than improvised.
- Dry mouth — the most common long-term effect. Modern intensity-modulated radiotherapy can spare enough parotid tissue that many patients keep useful saliva, but some dryness is usual.
- Skin reaction in the treated area, and hair loss in the back-of-head field.
- Change in taste, which usually recovers over months.
- Hearing change on the treated side, from the dose to the cochlea, which is why audiometry is a baseline test.
- Trismus and neck stiffness, which are reduced by starting jaw and neck exercises during treatment rather than after it.
The single most useful thing a patient can do is keep eating and drinking and keep doing the exercises, because losing weight during treatment worsens every other side effect and can force a break in the radiotherapy — which is the one outcome worth avoiding. That is why the plan includes dietetic support from the first week rather than at the point where eating has already become difficult.